CD19 and diffuse large B-cell lymphoma: Approved for treating DLBCL, loncastuximab tesirine (LT) is a CD19-directed ADC consisting of an anti-CD19 monoclonal antibody conjugated to cytotoxic alkylating agent via a cleavable linker with an average DAR of 2·3 (Lee, 2021).